IR@PKUHSC  > 北京大学药学院
学科主题药学
Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles
Feng, Qiang; Yu, Min-Zhi; Wang, Jian-Cheng; Hou, Wen-Jie; Gao, Ling-Yan; Ma, Xiao-Fei; Pei, Xi-Wei; Niu, Yu-Jie; Liu, Xiao-Yan; Qiu, Chong; Pang, Wen-Hao; Du, Li-Li; Zhang, Qiang
关键词Co-delivery Vegf Targeted Sirna Vapreotide Paclitaxel Core-shell Nanoparticle Tumor Targeting Therapy
刊名BIOMATERIALS
2014-06-01
DOI10.1016/j.biomaterials.2014.03.012
35期:18页:5028-5038
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Engineering, Biomedical ; Materials Science, Biomaterials
资助者National 973 Program of China ; NSFC Projects ; Beijing NSF Project ; Programs from Ministry of Education ; State Key Laboratory of Long-acting and Targeting Drug Delivery System, LUYE PHARMA ; National 973 Program of China ; NSFC Projects ; Beijing NSF Project ; Programs from Ministry of Education ; State Key Laboratory of Long-acting and Targeting Drug Delivery System, LUYE PHARMA
研究领域[WOS]Engineering ; Materials Science
关键词[WOS]ENDOTHELIAL GROWTH-FACTOR ; COMBRETASTATIN A-4 ; TUMOR-GROWTH ; SOMATOSTATIN RECEPTORS ; VASCULAR-PERMEABILITY ; RNA INTERFERENCE ; ANGIOGENESIS ; DOXORUBICIN ; THERAPEUTICS ; METASTASIS
英文摘要

A somatostatin analog, vapreotide (VAP), can be used as a ligand for targeting drug delivery based on its high affinity to somatostatin receptors (SSTRs), which is overexpressed in many tumor cells. RNA interference plays an important role on downregulation of vascular endothelial growth factor (VEGF), which is important for tumor growth, progression and metastasis. To improve tumor therapy efficacy, the vapreotide-modified core shell type nanoparticles co-encapsulating VEGF targeted siRNA (siVEGF) and paclitaxel (PTX), termed as VAP-PLPC/siRNA NPs, were developed in this study. When targeted via somatostatin receptors to tumor cells, the VAP-PLPC/siRNA NPs could simultaneously delivery siVEGF and PTX into cells and achieve a synergistic inhibition of tumor growth. Interestingly, in vitro cell uptake and gene silencing experiments demonstrated that the targeted VAP-PLPC/siRNA NPs exhibited significant higher intracellular siRNA accumulation and VEGF downregulation in human breast cancer MCF-7 cells, compared to those of the non-targeted PEG-PLPC/siRNA NPs. More importantly, in vivo results further demonstrated that the targeted VAP-PLPC/siRNA NPs had significant stronger drug distribution in tumor tissues and tumor growth inhibition efficacy via receptor-mediated targeting delivery, accompany with an obvious inhibition of neovascularization induced by siVEGF silencing. These results suggested that the co-delivery of siRNA and paclitaxel via vapreotide-modified core shell nanoparticles would be a promising approach for tumor targeted therapy. (C) 2014 Elsevier Ltd. All rights reserved.

语种英语
所属项目编号2013CB932501 ; 81273455 ; 81072597 ; 7112089 ; NCET-11-0014 ; BMU20110263
资助者National 973 Program of China ; NSFC Projects ; Beijing NSF Project ; Programs from Ministry of Education ; State Key Laboratory of Long-acting and Targeting Drug Delivery System, LUYE PHARMA ; National 973 Program of China ; NSFC Projects ; Beijing NSF Project ; Programs from Ministry of Education ; State Key Laboratory of Long-acting and Targeting Drug Delivery System, LUYE PHARMA
WOS记录号WOS:000335095900016
Citation statistics
Cited Times:57[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52108
Collection北京大学药学院
作者单位Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China
Recommended Citation
GB/T 7714
Feng, Qiang,Yu, Min-Zhi,Wang, Jian-Cheng,et al. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles[J]. BIOMATERIALS,2014,35(18):5028-5038.
APA Feng, Qiang.,Yu, Min-Zhi.,Wang, Jian-Cheng.,Hou, Wen-Jie.,Gao, Ling-Yan.,...&Zhang, Qiang.(2014).Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.BIOMATERIALS,35(18),5028-5038.
MLA Feng, Qiang,et al."Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles".BIOMATERIALS 35.18(2014):5028-5038.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Feng, Qiang]'s Articles
[Yu, Min-Zhi]'s Articles
[Wang, Jian-Cheng]'s Articles
百度学术
百度学术Similar articles in
[Feng, Qiang]'s Articles
[Yu, Min-Zhi]'s Articles
[Wang, Jian-Cheng]'s Articles
必应学术
必应学术Similar articles in
[Feng, Qiang]'s Articles
[Yu, Min-Zhi]'s Articles
[Wang, Jian-Cheng]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.